

**Relistor (methylnaltrexone)**  
**Effective 02/26/2018**

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

### Overview

Relistor is indicated for opioid-induced constipation in adults with chronic noncancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation.

### Coverage Guidelines

1. Member has a diagnosis of opioid-induced constipation (OIC) **AND**
2. Member has experienced an inadequate response or intolerance to treatment with at least two (2) different laxative agents (e.g., milk of magnesia, lactulose, polyethylene glycol [PEG], psyllium, senna, bisacodyl, etc.) **AND**
3. Member has experienced an inadequate response or intolerance to treatment with Amitiza<sup>®</sup> (lubiprostone).

### Limitations

1. Approvals will be granted for 12 months.

### References

1. Relistor (methylnaltrexone) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; March 2018
2. Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced disease. N Engl J Med. 2008; 358:2332-2343.
3. Michna E, Blonsky ER, Schulman S, Tzanis E, Manley A, Zhang H, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. Journal of Pain. 2011;12(5):554-62.



4. Anissian L, Schwartz HW, Vincent K, Vincent HK, Carpentino J, Stambler N, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. *Journal of Hospital Medicine*. 2012;7(2):67-72.
5. Rodrigues A, Wong C, Mattiussi A, Alexander S, Lau E, Dupuis LL. Methylnaltrexone for opioid-induced constipation in pediatric oncology patients. *Pediatric Blood & Cancer*. 2013;60(10):1667-70.
6. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of Pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. *American Journal of Gastroenterology*. 2013;108(10):1566-74.
7. Spierings ELH, Drossman DA, Cryer B, et al. Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes. *Pain Med* 2018; 19:1184.
8. Webster LR, Michna E, Khan A, et al. Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial. *Pain Med* 2017; 18:1496.

### **Review History**

00/00/09 – Implemented  
02/23/09 – Reviewed  
02/20/10 – Reviewed  
02/22/10 – Reviewed  
02/28/11 – Reviewed  
02/27/12 – Reviewed  
02/25/13 – Reviewed  
02/24/14 – Reviewed  
02/23/15 – Reviewed  
02/22/16 – Updated  
02/27/17 – Reviewed  
02/26/18 – Reviewed

### **Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.